Stocks and Investing
Stocks and Investing
Fri, December 16, 2022
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Akash Tewari Downgraded (THRD) to Hold and Decreased Target to $3.6 on, Dec 16th, 2022
Akash Tewari of Jefferies, Downgraded "Third Harmonic Bio, Inc." (THRD) to Hold and Decreased Target from $30 to $3.6 on, Dec 16th, 2022.
Akash has made no other calls on THRD in the last 4 months.
There is 1 other peer that has a rating on THRD. Out of the 1 peers that are also analyzing THRD, 0 agree with Akash's Rating of Hold.
This is the rating of the analyst that currently disagrees with Akash
- Joseph Thome of "Cowen & Co." Initiated at Buy on, Monday, October 10th, 2022
Contributing Sources